Literature DB >> 27875908

Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Sarah K Wendel1, Andrew F Longosz2, Susan H Eshleman3, Joel N Blankson2, Richard D Moore2, Jeanne C Keruly2, Thomas C Quinn1,2, Oliver Laeyendecker1,2.   

Abstract

We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).

Entities:  

Keywords:  ART; HIV; LAg; viral suppression

Mesh：

Substances：

Year:  2017        PMID： 27875908      PMCID： PMC5372761          DOI： 10.1089/AID.2016.0105

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  14 in total

1.  Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).

Authors:  M K Morris; D A Katzenstein; D Israelski; A Zolopa; R M Hendry; C V Hanson
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-15       Impact factor: 3.731

2.  Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion.

Authors:  Trudy Dobbs; Susan Kennedy; Chou-Pong Pau; J Steven McDougal; Bharat S Parekh
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

Review 3.  Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation.

Authors:  Michael P Busch; Christopher D Pilcher; Timothy D Mastro; John Kaldor; Gaby Vercauteren; William Rodriguez; Christine Rousseau; Thomas M Rehle; Alex Welte; Megan D Averill; Jesus M Garcia Calleja
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

4.  Two independent epidemics of HIV in Maryland.

Authors:  Jean K Carr; Anu Osinusi; Colin P Flynn; Bruce L Gilliam; Varun Maheshwari; Richard Y Zhao
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

5.  The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response.

Authors:  M Scott Killian; Philip J Norris; Bhupat D Rawal; Mila Lebedeva; Frederick M Hecht; Jay A Levy; Michael P Busch
Journal:  AIDS Res Hum Retroviruses       Date:  2006-07       Impact factor: 2.205

6.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort.

Authors:  R D Moore
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

7.  Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.

Authors:  Xierong Wei; Xin Liu; Trudy Dobbs; Debra Kuehl; John N Nkengasong; Dale J Hu; Bharat S Parekh
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

8.  Short Communication: Persistence of HIV Antibody Avidity in the Presence of Antiretroviral Therapy.

Authors:  Kelly A Curtis; Krystin Ambrose Price; Philip Niedzwiedz; Silvina Masciotra; Michele Owen
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04-19       Impact factor: 2.205

9.  Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.

Authors:  Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

10.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository.

Authors:  Reshma Kassanjee; Christopher D Pilcher; Sheila M Keating; Shelley N Facente; Elaine McKinney; Matthew A Price; Jeffrey N Martin; Susan Little; Frederick M Hecht; Esper G Kallas; Alex Welte; Michael P Busch; Gary Murphy
Journal:  AIDS       Date:  2014-10-23       Impact factor: 4.177
View more
  5 in total

1.  Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays.

Authors:  Jaythoon Hassan; Joanne Moran; Gary Murphy; Olivia Mason; Jeff Connell; Cillian De Gascun
Journal:  Med Microbiol Immunol       Date:  2019-03-11       Impact factor: 3.402

2.  Cross-Sectional HIV Incidence Estimation with Missing Biomarkers.

Authors:  Doug Morrison; Oliver Laeyendecker; Jacob Konikoff; Ron Brookmeyer
Journal:  Stat Commun Infect Dis       Date:  2018-07-31

3.  HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.

Authors:  Sheila M Keating; Christopher D Pilcher; Vivek Jain; Mila Lebedeva; Dylan Hampton; Mohamed Abdel-Mohsen; Xutao Deng; Gary Murphy; Alex Welte; Shelley N Facente; Frederick Hecht; Steven G Deeks; Satish K Pillai; Michael P Busch
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  Comprehensive Profiling of HIV Antibody Evolution.

Authors:  Susan H Eshleman; Oliver Laeyendecker; Kai Kammers; Athena Chen; Mariya V Sivay; Sanjay Kottapalli; Brandon M Sie; Tiezheng Yuan; Daniel R Monaco; Divya Mohan; Daniel Wansley; Tomasz Kula; Charles Morrison; Stephen J Elledge; Ron Brookmeyer; Ingo Ruczinski; H Benjamin Larman
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

5.  Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART).

Authors:  Wendy Grant-McAuley; Ethan Klock; Oliver Laeyendecker; Estelle Piwowar-Manning; Ethan Wilson; William Clarke; Autumn Breaud; Ayana Moore; Helen Ayles; Barry Kosloff; Kwame Shanaube; Peter Bock; Nomtha Mandla; Anneen van Deventer; Sarah Fidler; Deborah Donnell; Richard Hayes; Susan H Eshleman
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.752
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.